Metabolic Inflexibility with Obesity and the Effects of Fenofibrate on Skeletal Muscle Fatty Acid Oxidation

Overview

Journal Horm Metab Res

Specialty Endocrinology

Date 2017 Jan 20

PMID 28103623

Citations 7

Authors

Kristen E Boyle

Jacob E Friedman

Rachel C Janssen

Chantal Underkofler

Joseph A Houmard

Neda Rasouli

Affiliations

Soon will be listed here.

Abstract

This study was designed to investigate mechanisms of lipid metabolic inflexibility in human obesity and the ability of fenofibrate (FENO) to increase skeletal muscle fatty acid oxidation (FAO) in primary human skeletal muscle cell cultures (HSkMC) exhibiting metabolic inflexibility. HSkMC from 10 lean and 10 obese, insulin resistant subjects were treated with excess fatty acid for 24 h (24hFA) to gauge lipid-related metabolic flexibility. Metabolically inflexible HSkMC from obese individuals were then treated with 24hFA in combination with FENO to determine effectiveness for increasing FAO. Mitochondrial enzyme activity and FAO were measured in skeletal muscle from subjects with prediabetes (n=11) before and after 10 weeks of fenofibrate in vivo. 24hFA increased FAO to a greater extent in HSkMC from lean versus obese subjects (+49% vs. +9%, for lean vs. obese, respectively; p<0.05) indicating metabolic inflexibility with obesity. Metabolic inflexibility was not observed for measures of cellular respiration in permeabilized cells using carbohydrate substrate. Fenofibrate co-incubation with 24hFA, increased FAO in a subset of HSkMC from metabolically inflexible, obese subjects (p<0.05), which was eliminated by PPARα antagonist. In vivo, fenofibrate treatment increased skeletal muscle FAO in a subset of subjects with prediabetes but did not affect gene transcription or mitochondrial enzyme activity. Lipid metabolic inflexibility observed in HSkMC from obese subjects is not due to differences in electron transport flux, but rather upstream decrements in lipid metabolism. Fenofibrate increases the capacity for FAO in human skeletal muscle cells, though its role in skeletal muscle metabolism in vivo remains unclear.

Citing Articles

Lipidomics of infant mesenchymal stem cells associate with the maternal milieu and child adiposity.

Gyllenhammer L, Zaegel V, Duensing A, Lixandrao M, Dabelea D, Bergman B JCI Insight. 2024; 9(19).

PMID: 39226911 PMC: 11466181. DOI: 10.1172/jci.insight.180016.

The Response of Mitochondrial Respiration and Quantity in Skeletal Muscle and Adipose Tissue to Exercise in Humans with Prediabetes.

Szczerbinski L, Taylor M, Puchta U, Konopka P, Paszko A, Citko A Cells. 2021; 10(11).

PMID: 34831236 PMC: 8616473. DOI: 10.3390/cells10113013.

Metabolic Response to Submaximal and Maximal Exercise in People with Severe Obesity, Prediabetes, and Diabetes.

Battista F, Belligoli A, Neunhaeuserer D, Gasperetti A, Bettini S, Compagnin C Obes Facts. 2021; 14(4):415-424.

PMID: 34344002 PMC: 8406246. DOI: 10.1159/000517589.

Maternal metabolic health drives mesenchymal stem cell metabolism and infant fat mass at birth.

Erickson M, Patinkin Z, Duensing A, Dabelea D, Redman L, Boyle K JCI Insight. 2021; 6(13.

PMID: 34061777 PMC: 8410068. DOI: 10.1172/jci.insight.146606.

Metabolic Flexibility as an Adaptation to Energy Resources and Requirements in Health and Disease.

Smith R, Soeters M, Wust R, Houtkooper R Endocr Rev. 2018; 39(4):489-517.

PMID: 29697773 PMC: 6093334. DOI: 10.1210/er.2017-00211.

References

Kelley D, Goodpaster B, Wing R, Simoneau J . Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol. 1999; 277(6):E1130-41. DOI: 10.1152/ajpendo.1999.277.6.E1130. View

Idzior-Walus B, Sieradzki J, Rostworowski W, Zdzienicka A, Kawalec E, Wojcik J . Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest. 2000; 30(10):871-8. DOI: 10.1046/j.1365-2362.2000.00734.x. View

Mancini F, Lanni A, Sabatino L, Moreno M, Giannino A, Contaldo F . Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats. FEBS Lett. 2001; 491(1-2):154-8. DOI: 10.1016/s0014-5793(01)02146-9. View

Furuhashi M, Ura N, Murakami H, Hyakukoku M, Yamaguchi K, Higashiura K . Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and beta-oxidation in skeletal muscle. J Endocrinol. 2002; 174(2):321-9. DOI: 10.1677/joe.0.1740321. View

Yoon M, Jeong S, Lee H, Han M, Kang J, Kim E . Fenofibrate improves lipid metabolism and obesity in ovariectomized LDL receptor-null mice. Biochem Biophys Res Commun. 2003; 302(1):29-34. DOI: 10.1016/s0006-291x(03)00088-3. View

Hulver M, Berggren J, Cortright R, Dudek R, Thompson R, Pories W . Skeletal muscle lipid metabolism with obesity. Am J Physiol Endocrinol Metab. 2003; 284(4):E741-7. DOI: 10.1152/ajpendo.00514.2002. View

Boston R, Stefanovski D, Moate P, Sumner A, Watanabe R, Bergman R . MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther. 2004; 5(6):1003-15. DOI: 10.1089/152091503322641060. View

Jeong S, Han M, Lee H, Kim M, Kim J, Nicol C . Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice. Metabolism. 2004; 53(10):1284-9. DOI: 10.1016/j.metabol.2004.05.003. View

Menshikova E, Ritov V, Toledo F, Ferrell R, Goodpaster B, Kelley D . Effects of weight loss and physical activity on skeletal muscle mitochondrial function in obesity. Am J Physiol Endocrinol Metab. 2004; 288(4):E818-25. DOI: 10.1152/ajpendo.00322.2004. View

10.

Kon Koh K, Han S, Quon M, Ahn J, Shin E . Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care. 2005; 28(6):1419-24. DOI: 10.2337/diacare.28.6.1419. View

11.

Kelley D . Skeletal muscle fat oxidation: timing and flexibility are everything. J Clin Invest. 2005; 115(7):1699-702. PMC: 1159159. DOI: 10.1172/JCI25758. View

12.

Lee W, Kim M, Park H, Kim H, Jeon M, Oh K . AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARalpha and PGC-1. Biochem Biophys Res Commun. 2005; 340(1):291-5. DOI: 10.1016/j.bbrc.2005.12.011. View

13.

Murakami H, Murakami R, Kambe F, Cao X, Takahashi R, Asai T . Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC. Biochem Biophys Res Commun. 2006; 341(4):973-8. DOI: 10.1016/j.bbrc.2006.01.052. View

14.

Anderlova K, Dolezalova R, Housova J, Bosanska L, Haluzikova D, Kremen J . Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes. Physiol Res. 2006; 56(5):579-586. DOI: 10.33549/physiolres.931058. View

15.

Boushel R, Gnaiger E, Schjerling P, Skovbro M, Kraunsoe R, Dela F . Patients with type 2 diabetes have normal mitochondrial function in skeletal muscle. Diabetologia. 2007; 50(4):790-6. PMC: 1820754. DOI: 10.1007/s00125-007-0594-3. View

16.

Mogensen M, Sahlin K, Fernstrom M, Glintborg D, Vind B, Beck-Nielsen H . Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes. Diabetes. 2007; 56(6):1592-9. DOI: 10.2337/db06-0981. View

17.

Cree M, Newcomer B, Read L, Sheffield-Moore M, Paddon-Jones D, Chinkes D . Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-alpha agonist treatment. Mech Ageing Dev. 2007; 128(10):558-65. PMC: 3503242. DOI: 10.1016/j.mad.2007.08.001. View

18.

Berggren J, Boyle K, Chapman W, Houmard J . Skeletal muscle lipid oxidation and obesity: influence of weight loss and exercise. Am J Physiol Endocrinol Metab. 2008; 294(4):E726-32. DOI: 10.1152/ajpendo.00354.2007. View

19.

Anderson E, Lustig M, Boyle K, Woodlief T, Kane D, Lin C . Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest. 2009; 119(3):573-81. PMC: 2648700. DOI: 10.1172/JCI37048. View

20.

Corpeleijn E, Saris W, Blaak E . Metabolic flexibility in the development of insulin resistance and type 2 diabetes: effects of lifestyle. Obes Rev. 2009; 10(2):178-93. DOI: 10.1111/j.1467-789X.2008.00544.x. View